Canadian Cancer Trials Group Bulletins

General


Recent Publications

Canadian Cancer Trials Group BR.10 (A Phase III Prospective Randomized Study of Adjuvant Chemotherapy with Vinorelbine and Cisplatin in Completely Resected Non-Small Cell Lung Cancer with Companion Tumour Marker Evaluation) / Lung Adjuvant Cisplatin Evaluation (LACE-Bio) Consortium

Shepherd FA, Domerg C, Hainaut P, Jšnne PA, Pignon JP, Graziano S, Douillard J-Y, Brambilla E, Le Chevalier T, Seymour L, Bourredjem A, Le Teuff G, Pirker R, Filipits M, Rosell R, Kratzke R, Bandarchi B, Ma X, Capelletti M, Soria J-C, Tsao MS. Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy (ONLINE). J Clin Oncol 2013.

http://jco.ascopubs.org/content/early/2013/04/29/JCO.2012.48.1390.abstract

_________________________________


Canadian Cancer Trials Group CM.1 (SWOG S0325) - A Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased Doses for or Dasatinib (BMS 354825) (NSC-732517) for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase (Primary for Dose Level 1 (400 mg))

Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Druker BJ. A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia. Blood 120: 3898-905, 2012.

http://bloodjournal.hematologylibrary.org/content/120/19/3898.abstract

_________________________________


Canadian Cancer Trials Group MA.12 - Double-Blind Randomized Trial of Tamoxifen versus Placebo in Patients with Node Positive or High Risk Node Negative Breast Cancer Who Have Completed CMF, CEF or AC Adjuvant Chemotherapy

Yan Y, Li X, Blanchard A, Bramwell VHC, Pritchard KI, Tu D, Shepherd L, Myal Y, Penner C, Watson PH, Leygue E, Murphy LC. Expression of both Estrogen Receptor-beta 1 (ER-b1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-a)-Negative Early Breast Cancer (EBC) (ONLINE). Ann Oncol 2013.

http://annonc.oxfordjournals.org/content/early/2013/04/10/annonc.mdt132.abstract

_________________________________


Canadian Cancer Trials Group MA.27 - A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer

Vachon CM, Suman VJ, Brandt KR, Kosel ML, Buzdar AU, Olson JE, Wu FF, Flickinger LM, Ursin G, Elliott CR, Shepherd L, Weinshilboum RM, Goss PE, Ingle JN. Mammographic Breast Density Response to Aromatase Inhibition. Clin Cancer Res 19: 2144-53, 2013.

http://clincancerres.aacrjournals.org/content/19/8/2144.abstract">http://clincancerres.aacrjournals.org/content/19/8/2144.abstract

_________________________________


Canadian Cancer Trials Group HD.7 (ECOG E2496) - A Randomized Phase III Trial of ABVD versus Stanford V with or without Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease

Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh Ws, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl BS, Horning SJ, Ambinder RF. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 121: 3547-53, 2013.

http://bloodjournal.hematologylibrary.org/content/121/18/3541.full